How is Clinical Trial Reimbursement Money Spent? South African Trial Participants' Reported Reimbursement Spending Patterns and Perceptions of Appropriate Reimbursement Amounts.
Clinical trial participation
Reimbursement
South Africa
Vulnerable participants
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
accepted:
30
07
2021
pubmed:
12
8
2021
medline:
8
2
2022
entrez:
11
8
2021
Statut:
ppublish
Résumé
Reimbursement of participants in clinical trials is extensively debated. Guidance recommends that compensation should reflect time, inconvenience and reimbursement of expenses. This study describes how participants spend their reimbursement and perceptions of appropriate reimbursement amounts. This was a sub-study of the evidence for contraceptive options and HIV outcomes (ECHO) trial. Participants were from two sites in KwaZulu-Natal, South Africa. A mixed methods approach was used. 500 participants completed a questionnaire, and 32 participated in one of four focus group discussions (FGD). The majority (81%) used reimbursement for transport to the research site, followed by toiletry purchases (64%). Many described how reimbursement supplemented income, used to cover basic living costs. Some used money to buy luxury items and takeaway foods. The ideal reimbursement amount per visit ranged: ZAR150-ZAR340 (US$10-24). Reimbursement spending and perceptions are in line with local guidance. Reimbursement should consider risk minimization together with ensuring informed, voluntary decision making.
Identifiants
pubmed: 34379272
doi: 10.1007/s10461-021-03418-2
pii: 10.1007/s10461-021-03418-2
pmc: PMC8813833
doi:
Substances chimiques
Contraceptive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
604-612Subventions
Organisme : Bill and Melinda Gates Foundation
ID : OPP1032115
Organisme : United States Agency for International Development
ID : AID-OAA-A-15-00045
Organisme : the Swedish International Development Cooperation Agency
ID : 2017/762965-0
Informations de copyright
© 2021. The Author(s).
Références
Perspect Clin Res. 2013 Jan;4(1):70-4
pubmed: 23533986
BMC Public Health. 2018 Jan 10;18(1):120
pubmed: 29316885
J Med Ethics. 2008 May;34(5):389-92
pubmed: 18448723
J Med Ethics. 2015 Nov;41(11):909-13
pubmed: 26392172
J Law Med Ethics. 2009 Spring;37(1):19-27
pubmed: 19245599
S Afr Med J. 2008 Feb;98(2):95-7
pubmed: 18350200
Clin Trials. 2020 Jun;17(3):264-272
pubmed: 32063065
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
J Med Ethics. 2010 Jan;36(1):34-6
pubmed: 20026691
J Med Ethics. 2004 Jun;30(3):293-8
pubmed: 15173366
J Empir Res Hum Res Ethics. 2011 Sep;6(3):31-8
pubmed: 21931235
BMC Womens Health. 2019 Jan 25;19(1):18
pubmed: 30683103
Patient Prefer Adherence. 2012;6:579-88
pubmed: 22936844
Bioethics. 2003 Oct;17(5-6):472-86
pubmed: 14959716
Bull Med Ethics. 2002 Oct;(182):17-23
pubmed: 14983848
Lancet. 2019 Jul 27;394(10195):303-313
pubmed: 31204114
IRB. 2012 Jan-Feb;34(1):1-8
pubmed: 22338401
Am J Bioeth. 2005 Sep-Oct;5(5):9-13; discussion W8-11, W17
pubmed: 16179296